Patents by Inventor Stephen Chappell
Stephen Chappell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110320422Abstract: Systems and methods are provided to deliver business information to users through users' online address books. Data aggregation servers associate individual businesses with one or more unique identifiers. The data aggregation servers collect, store and periodically update business information relating to individual businesses from a variety of sources, such as the businesses themselves and third party sources, such as online publications and message boards. The data aggregation servers store the information in association with the unique identifier. Electronic address book applications hosted on user devices store address book entries for individual businesses in local address book databases. The entries for each business include the unique identifier, and the online address book applications use the unique identifier to retrieve business information relating to individual businesses from the data aggregation servers.Type: ApplicationFiled: June 28, 2010Publication date: December 29, 2011Applicant: AT&T MOBILITY II LLCInventors: Jack Denenberg, Ely Shemesh, Stephen Chappell
-
Publication number: 20110318371Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.Type: ApplicationFiled: June 13, 2011Publication date: December 29, 2011Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Patent number: 8053551Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: April 4, 2003Date of Patent: November 8, 2011Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Patent number: 7968307Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.Type: GrantFiled: October 7, 2009Date of Patent: June 28, 2011Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Patent number: 7928201Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.Type: GrantFiled: October 7, 2009Date of Patent: April 19, 2011Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Publication number: 20100272742Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.Type: ApplicationFiled: April 16, 2010Publication date: October 28, 2010Inventors: Daniel E. AFAR, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Patent number: 7803916Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.Type: GrantFiled: September 16, 2008Date of Patent: September 28, 2010Assignee: Agensys Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Stephen Chappell Mitchell
-
Publication number: 20100190962Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.Type: ApplicationFiled: October 7, 2009Publication date: July 29, 2010Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Publication number: 20100173297Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.Type: ApplicationFiled: October 7, 2009Publication date: July 8, 2010Inventors: DANIEL E. AFAR, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Publication number: 20100036807Abstract: Systems and methods sort location dependent information based on selecting multiple groups of information according to location, ordering the groups based on location, and ordering the information within the groups based on at least one or more other criteria. The size(s) of the areas used to select the groups may be predetermined, or dynamically determined (e.g., based on clustering of information along distance to a location of interest).Type: ApplicationFiled: August 5, 2008Publication date: February 11, 2010Applicant: YELLOWPAGES.COM LLCInventors: Jay H. LIESKE, JR., Stephen CHAPPELL
-
Patent number: 7642054Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STRAP” Serpentine TRansmembrane Antigens of the Prostate). Four particular human STRAPs are described and characterized herein. The human STRAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STRAP family, STRAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STRAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and Intracellular N- and C-termini, suggesting that It folds In a “serpentine” manner Into three extracellular and two intracellular loops.Type: GrantFiled: September 12, 2005Date of Patent: January 5, 2010Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Publication number: 20090307018Abstract: Systems and methods are provided to facilitate the presentation of listings according to levels of user interest in the listings. For example, statistics generated from tracking user interactions with the listings and/or other parameters can be used to measure or estimate a level of current user interest in a listing. Listings in search results can be presented in an order according to the levels of current user interest in the listings.Type: ApplicationFiled: June 6, 2008Publication date: December 10, 2009Applicant: YELLOWPAGES COM, LLCInventors: Stephen Chappell, Jay H. Lieske, JR., Samantha Nebrich
-
Publication number: 20090307318Abstract: Systems and methods are provided to specify a location of a planned event via a selection of a listing that has location information. For example, in response to a search request a listing may show a business entity at a geographic location; and the user may select the listing as a way to specify the location of a new event or an existing event. In some embodiments, one event can have multiple listings specifying multiple locations.Type: ApplicationFiled: June 6, 2008Publication date: December 10, 2009Applicant: YELLOWPAGES COM, LLCInventors: Stephen Chappell, Jay H. Lieske, JR., Samantha Nebrich
-
Publication number: 20090307268Abstract: Systems and methods are provided to specify a location of a planned event via a selection of a listing that has location information. For example, in response to a search request a listing may show a business entity at a geographic location; and the user may select the listing as a way to specify the location of a new event or an existing event. In some embodiments, one event can have multiple listings specifying multiple locations.Type: ApplicationFiled: June 30, 2008Publication date: December 10, 2009Applicant: Yellowpages.com LLCInventors: Stephen CHAPPELL, Jay H. LIESKE, JR., Samantha NEBRICH
-
Patent number: 7611904Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (SIX Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: October 12, 2006Date of Patent: November 3, 2009Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Publication number: 20090098629Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.Type: ApplicationFiled: September 16, 2008Publication date: April 16, 2009Inventors: Daniel E. AFAR, Rene S. Hubert, Stephen Chappell Mitchell
-
Publication number: 20090093049Abstract: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating ilie oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.Type: ApplicationFiled: November 6, 2008Publication date: April 9, 2009Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Frederick S. Jones, Geoffrey Owens, Robyn Meech
-
Patent number: 7485299Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: October 10, 2006Date of Patent: February 3, 2009Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Patent number: 7468275Abstract: Synthetic and isolated translational regulatory elements, including oligonucleotides that have translational enhancing activity, internal ribosome entry site (IRES) activity, or translational inhibitory activity, and multimers of such translational regulatory elements are provided. In addition, compositions that include such translational regulatory elements are provided, as are methods of using the translational regulatory elements.Type: GrantFiled: January 26, 2001Date of Patent: December 23, 2008Assignee: The Scripps Research InstituteInventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Geoffrey Owens, Jason K. Pinkstaff, Leslie Krushel, Wei Zhou
-
Patent number: 7456273Abstract: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating ilie oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.Type: GrantFiled: November 29, 2006Date of Patent: November 25, 2008Assignee: The Scripps Research InstituteInventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Frederick S. Jones, Geoffrey Owens, Robyn Meech